Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AM2PAT Inc. was a North Carolina-based manufacturer of pre-filled heparin and saline syringes that became the center of a major public health crisis in 2007 and 2008. The company's products were found to be contaminated with Serratia marcescens bacteria due to severe manufacturing violations and a lack of proper sterility testing. This contamination resulted in at least five deaths and over 300 infections across multiple states, leading to a massive nationwide recall. Following a federal investigation, the company was shut down, and its manufacturing facility in Angier, North Carolina, was closed. Several top executives were sentenced to prison for fraud and distributing adulterated medical products, while the CEO, Dushyant Patel, fled the country to avoid prosecution.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AM2PAT.